Modality
Fusion Protein
MOA
CGRPant
Target
VEGF
Pathway
Wnt
MDDSCDNSCLC
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
~Oct 2019
→ ~Jan 2021
Phase 3
~Apr 2021
→ ~Jul 2022
NDA/BLA
Oct 2022
→ Nov 2031
NDA/BLACurrent
NCT07636934
994 pts·NSCLC
2022-10→2031-11·Completed
994 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-165.6y awayPh3 Readout· NSCLC
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2031-11-16 · 5.6y away
NSCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07636934 | NDA/BLA | NSCLC | Completed | 994 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |